Fessler Joachim, Gross Joseph, Papendick Heike, Schubert Ingrid
Z Arztl Fortbild Qualitatssich. 2006;100(2):107-12.
The aims of the study were to determine whether the participants of a practitioners' network changed their prescribing behaviour according to the guidelines discussed and to assess the implications for drug costs. Guidelines concerning the prescription of lipid-lowering drugs, antidiabetics and cardiovascular drugs were introduced in quality circles with about 90 participants in a practitioners' network. All statutory health care insurance physicians of Hesse served as comparison group. The analysis of the prescription data demonstrates that the network physicians attained their pre-determined quality goals but differed with respect to the cost implications for the drug target classes. Higher prescribing rates for recommended though more expensive drugs do not necessarily raise the drug costs of the indication group, which is partly due to the substitution of other drugs. The implications on treatment costs by implementing a guideline should be assessed for all sectors of the healthcare system. This kind of data was not available for this study. It is becoming increasingly relevant to know the cost implications of a guideline recommendation since (suspected) higher costs appear to be a barrier for guideline adherence.
该研究的目的是确定从业者网络的参与者是否根据所讨论的指南改变其处方行为,并评估对药物成本的影响。在一个从业者网络中,针对约90名参与者的质量改进小组引入了有关降脂药物、抗糖尿病药物和心血管药物处方的指南。黑森州所有法定医疗保险医生作为对照组。对处方数据的分析表明,网络医生达到了他们预先设定的质量目标,但在药物目标类别对成本的影响方面存在差异。推荐使用但更昂贵药物的更高处方率不一定会提高适应症组的药物成本,部分原因是其他药物的替代。对于医疗保健系统的所有部门,都应评估实施指南对治疗成本的影响。本研究没有此类数据。了解指南建议对成本的影响变得越来越重要,因为(疑似)更高的成本似乎是遵循指南的一个障碍。